These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 16371014)

  • 1. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.
    Thursky KA; Worth LJ; Seymour JF; Miles Prince H; Slavin MA
    Br J Haematol; 2006 Jan; 132(1):3-12. PubMed ID: 16371014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab therapy in B-cell lymphoproliferative disorders.
    Moreton P; Hillmen P
    Semin Oncol; 2003 Aug; 30(4):493-501. PubMed ID: 12939718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies.
    Borthakur G; Lin E; Faderl S; Ferrajoli A; Wierda W; Giles F; Browning ML; Kantarjian H; Keating M; O'Brien S
    Cancer; 2007 Dec; 110(11):2478-83. PubMed ID: 17960607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia.
    Saadeh CE; Srkalovic G
    Pharmacotherapy; 2008 Feb; 28(2):281-4. PubMed ID: 18225973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab in T-cell lymphoproliferative disorders.
    Dearden CE; Matutes E
    Best Pract Res Clin Haematol; 2006; 19(4):795-810. PubMed ID: 16997184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
    Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.
    Vallejo C; Ríos E; de la Serna J; Jarque I; Ferrá C; Sánchez-Godoy P; Solano C; de la Cámara R; Rosell AI; Varela R; García MD; González-Barca E; López J; Pérez E; Ferrer S; Casado LF; Vázquez L; Villalón L; García-Marco JA
    Expert Rev Hematol; 2011 Feb; 4(1):9-16. PubMed ID: 21322774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
    Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras C; Vassilakopoulos TP; Vaiopoulos G; Siakantaris MP
    Med Oncol; 2001; 18(2):99-107. PubMed ID: 11778765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.
    Martin SI; Marty FM; Fiumara K; Treon SP; Gribben JG; Baden LR
    Clin Infect Dis; 2006 Jul; 43(1):16-24. PubMed ID: 16758413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
    Laros-van Gorkom BA; Huisman CA; Wijermans PW; Schipperus MR
    Neth J Med; 2007 Oct; 65(9):333-8. PubMed ID: 17954952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab in Sézary syndrome: efficient but not innocent.
    Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
    Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Campath-1H.
    Sorokin P
    Clin J Oncol Nurs; 2001; 5(2):65-6. PubMed ID: 11899778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
    Dumont FJ
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab for B-cell chronic lymphocytic leukemia.
    Robak T
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab.
    Ravandi F; O'Brien S
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):39-51. PubMed ID: 15757437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders.
    Gibbs SD; Westerman DA; McCormack C; Seymour JF; Miles Prince H
    Br J Haematol; 2005 Jul; 130(1):87-91. PubMed ID: 15982349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
    Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
    Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
    Ferrajoli A; O'Brien SM; Cortes JE; Giles FJ; Thomas DA; Faderl S; Kurzrock R; Lerner S; Kontoyiannis DP; Keating MJ
    Cancer; 2003 Aug; 98(4):773-8. PubMed ID: 12910522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab (Campath 1-H).
    Schaal AD
    Clin J Oncol Nurs; 2005 Oct; 9(5):630-2. PubMed ID: 16235592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on prophylaxis and therapy of infection in patients with chronic lymphocytic leukemia.
    Morrison VA
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):84-90. PubMed ID: 12113137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.